10-Q: IRIDEX Reports Q3 Revenue Growth, Reduced Operating Loss

Sentiment:

Quarterly Report 12 November 2025 4:25 PM

IRIDEX Corporation announced increased revenues and a narrower operating loss for the third quarter and first nine months of fiscal year 2025, driven by product sales and cost-saving measures.

Capital raiseOn March 19, 2025, the company issued 600,000 shares of Series B Preferred Stock at $10.00 per share, initially convertible into 3,000,000 shares of common stock.Concurrently, an Initial Convertible Promissory Note for $4,000,000 was issued to Novel Inspirational International Co., Ltd., convertible into 400,000 shares of Series B Preferred Stock.Novel Inspirational International Co., Ltd. has the right to purchase additional convertible promissory notes (Growth Notes) in an aggregate principal amount of $10,000,000, issuable in three annual installments after March 19, 2025.

Better than expectedTotal revenues increased by 7.8% for the three months and 5.5% for the nine months, indicating positive top-line growth.Loss from operations significantly narrowed by $0.46 million for the three months and $5.24 million for the nine months, demonstrating improved operational efficiency.Net cash used in operating activities decreased by $3.34 million for the nine months, reflecting better cash flow management.Net loss improved by $0.36 million for the three months and $3.82 million for the nine months, despite a significant one-time loss from debt extinguishment.

Summary

Total revenues for the three months ended September 27, 2025, increased by $0.9 million, or 7.8%, to $12.5 million, compared to $11.6 million for the same period in 2024.
Total revenues for the nine months ended September 27, 2025, increased by $2.0 million, or 5.5%, to $38.0 million, compared to $36.0 million for the same period in 2024.
Gross profit for the three months decreased by 7.2% to $4.0 million, with gross margin declining to 32.1% from 37.3%, primarily due to an $0.8 million inventory write-down.
Gross profit for the nine months decreased by 1.2% to $13.8 million, with gross margin declining to 36.2% from 38.7%, also impacted by the inventory write-down.
Operating expenses for the three months decreased by 12.4% to $5.4 million, and for the nine months decreased by 24.9% to $16.3 million, largely due to cost savings measures including lower headcount and consulting costs.
Net loss for the three months improved to $(1.6) million from $(1.9) million, and for the nine months improved to $(4.3) million from $(8.1) million.
Net cash used in operating activities significantly improved to $(2.7) million for the nine months, compared to $(6.0) million in the prior year period.
The company raised $6.0 million in net cash from financing activities during the nine months, primarily from the issuance of convertible preferred shares and convertible debt.
An early repayment of the Lind Note on March 19, 2025, resulted in a $1.3 million loss on extinguishment, contributing to a higher 'Other expense, net' for the nine-month period.

Sentiment

Score: 6

Explanation: The company demonstrated revenue growth and significant improvements in operating loss and cash flow from operations, supported by effective cost-saving measures and a successful capital raise. However, these positives are tempered by a decline in gross margin due to an inventory write-down, an increased accumulated deficit, and a substantial one-time loss from debt extinguishment. Macroeconomic headwinds and customer concentration also present ongoing challenges.

Positives

Total revenues increased by 7.8% for the three months and 5.5% for the nine months ended September 27, 2025, demonstrating continued product demand.
Loss from operations significantly improved, decreasing by $0.46 million for the three months and $5.24 million for the nine months, reflecting effective cost-saving measures.
Net cash used in operating activities improved by $3.34 million for the nine months, indicating better cash management and operational efficiency.
Cash and cash equivalents increased to $5.6 million as of September 27, 2025, from $2.4 million at December 28, 2024, bolstering liquidity.
Working capital increased to $11.7 million from $7.0 million, improving the company's short-term financial health.
Successful capital raise through the issuance of Series B Preferred Stock and an Initial Novel Note, providing $10.0 million in new capital.

Negatives

Gross profit decreased by 7.2% for the three months and 1.2% for the nine months, primarily due to an $0.8 million inventory write-down in the third quarter of 2025.
Gross margin declined by 5.2 percentage points for the three months (to 32.1%) and 2.5 percentage points for the nine months (to 36.2%).
Accumulated deficit increased to $(92.3) million as of September 27, 2025, from $(88.0) million at December 28, 2024, indicating continued net losses.
Other expense, net, significantly increased to $(1.7) million for the nine months, primarily due to a $1.3 million loss on the early extinguishment of the Lind Note.
The company continues to incur net losses, with $(1.6) million for the three months and $(4.3) million for the nine months ended September 27, 2025.

Risks

Macroeconomic conditions, including recessionary fears, inflation, tariffs, geopolitical uncertainty, and heightened interest rates, may continue to negatively impact capital equipment purchasing demand and extend customer purchase decision cycles.
A strengthening U.S. dollar could cause products to become relatively more expensive for international customers, potentially leading to reduced revenue or profitability.
Significant customer concentration risk exists, with Topcon Corporation accounting for 31% and 32% of total revenues for the three and nine months ended September 27, 2025, respectively, and 25% of accounts receivable.
The company's common stock price fluctuations could impact the fair value of its reporting unit and lead to potential goodwill impairment in future periods.
Future capital requirements depend on growth rate, R&D spending, sales and marketing expansion, new product introductions, and manufacturing technologies, and additional equity issuances could dilute existing stockholders.
The company is subject to various laws, policies, and regulations in the U.S. and internationally, and failure to comply could adversely affect the business.

Future Outlook

The company believes the market for its products remains strong but acknowledges that the overall capital expenditure landscape within healthcare facilities may continue to be negatively impacted by persistent macroeconomic concerns, including geopolitical uncertainty, tariffs, trade wars, and a strengthening U.S. dollar. Management expects existing cash and cash equivalents to be sufficient to meet anticipated cash needs over the next 12 months, but future capital requirements will depend on growth rate, R&D spending, sales and marketing expansion, and new product introductions.

Management Comments

Believe the market for our products remains strong, despite macroeconomic headwinds.
The overall capital expenditure landscape within hospitals, surgical centers and physician offices may continue to be negatively impacted by persistent macroeconomic concerns, including those from ongoing geopolitical uncertainty, tariffs and trade wars.
Implemented cost savings measures, resulting in lower headcount expenses and curtailed spending on new and expanded products in research and development.
Continued realizing cost savings from lower headcount and being disciplined with our expenses in sales and marketing.
Believe existing cash and cash equivalents will be sufficient to meet anticipated cash needs over the next 12 months.

Industry Context

The ophthalmic medical technology industry is experiencing challenges in capital equipment purchasing due to broader macroeconomic conditions such as recessionary fears, inflation, and geopolitical uncertainty. These factors are extending purchase decision cycles for hospitals, surgical centers, and physician offices. A strong U.S. dollar also poses a risk to international sales by making products more expensive for customers in other regions.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Charter Amendment	Stockholders approved an amendment and restatement of the Company's Amended and Restated Certificate of Incorporation, increasing the number of authorized common stock shares from 30,000,000 to 63,500,000 shares.	2025-06-11	Increases flexibility for future equity issuances, including for capital raises or employee incentive plans, but also introduces potential for dilution.
Equity Incentive Plan Amendment	Stockholders approved adding 1,000,000 shares to the 2008 Equity Incentive Plan and extended its term.	2025-06-11	Provides more shares for employee and director compensation, aligning incentives but potentially increasing stock-based compensation expense and dilution.
Preferred Stock Reclassification	Series B Preferred Stock was reclassified from mezzanine equity to permanent equity following stockholder approval of the Restated Charter, which revised certain provisions.	Q2 2025	Reflects a more stable capital structure from an accounting perspective, indicating the Series B Preferred Stock now meets the definition of permanent equity.

Legal Proceedings

The company may be involved in legal proceedings arising in the ordinary course of business. Management believes the final outcome of these matters will not have a material adverse effect on the business, operating results, financial condition, or cash flows. Litigation can, however, have an adverse impact due to defense and settlement costs and diversion of management resources.

Related Party Transactions

Topcon Corporation, a principal owner with a 10% voting interest, accounted for approximately $3.9 million (31%) and $12.0 million (32%) of total revenues for the three and nine months ended September 27, 2025, respectively, including exclusive distribution rights revenue.
The company purchased approximately $0.1 million and $0.4 million in raw materials from Topcon during the three and nine months ended September 27, 2025, respectively.
As of September 27, 2025, amounts receivable from Topcon were $2.4 million and payable to Topcon were $0.2 million.
Novel Inspirational International Co., Ltd. (Novel) purchased 600,000 shares of Series B Preferred Stock and an Initial Convertible Promissory Note for $4.0 million on March 19, 2025. Novel also has the right to appoint two individuals to the company's board of directors and approve certain corporate actions.

Stakeholder Impact

Shareholders face potential dilution from future issuances of equity, including the Growth Notes and shares under the amended equity incentive plan.
Employees may be impacted by continued cost-saving measures, including headcount reductions, as seen in decreased R&D, sales & marketing, and G&A expenses.
Customers, particularly international ones, may experience higher product costs if the U.S. dollar strengthens, potentially leading to reduced demand.
Creditors (Novel) benefit from the 12% interest rate on the Initial Novel Note and the right to purchase additional Growth Notes, providing a stable return and potential for further investment.

Next Steps

Novel Inspirational International Co., Ltd. has the right to purchase additional convertible promissory notes (Growth Notes) in three installments on each yearly anniversary after March 19, 2025.
The company will continue to assess the tax accounting impacts of The One Big Beautiful Bill (OBBB) Act and various state legislation and conformity rules, recording any tax impact in the third quarter of 2025.

Key Dates

Date	Description
2023-09-30	Company began utilizing its ERP system, with amortization of capitalized implementation costs over five years.
2024-08-04	Date of Securities Purchase Agreement with Lind Global Asset Management IX LLC.
2024-08-07	Date of Senior Convertible Promissory Note issued to Lind Global Asset Management IX LLC.
2024-12-28	Fiscal year end for which the Annual Report on Form 10-K was filed.
2025-03-18	Company filed a Certificate of Designation, Preferences and Rights of the Series B Preferred Stock.
2025-03-19	Company entered into a securities purchase agreement and a note purchase agreement with Novel Inspirational International Co., Ltd., and fully discharged outstanding obligations under the Lind Note.
2025-03-27	Annual Report on Form 10-K for the fiscal year ended December 28, 2024, was filed with the SEC.
2025-04-28	Company's definitive proxy statement filed with the SEC.
2025-05-20	Company's definitive additional materials filed with the SEC, supplementing proxy statement.
2025-06-02	Company's definitive additional materials filed with the SEC, supplementing proxy statement.
2025-06-11	Company's annual meeting of stockholders where an amendment and restatement of the Company's Amended and Restated Certificate of Incorporation was approved, and the Restated Charter was filed with the Secretary of State of Delaware.
2025-07-01	First business day of calendar quarter for interest payment on Initial Novel Note.
2025-07-04	President Trump signed The One Big Beautiful Bill (OBBB) Act, including comprehensive U.S. corporate tax legislation.
2025-09-27	End of the quarterly period covered by this Form 10-Q.
2025-11-06	Number of common stock shares issued and outstanding was 17,189,981.
2025-11-12	Date of filing of this Quarterly Report on Form 10-Q.
2026-12-15	Effective date for ASU 2024-03 (Income Statement Expense Disaggregation Disclosures) for fiscal years beginning after this date.
2027-12-15	Effective date for ASU 2024-03 (Income Statement Expense Disaggregation Disclosures) for interim periods within fiscal years beginning after this date.
2028-03-19	Maturity date for the Initial Novel Note.

Recommendation

hold

While IRIDEX demonstrated revenue growth and significant improvements in operational efficiency, leading to a narrower net loss and better cash flow from operations, several factors warrant a 'hold' recommendation. The gross margin decline due to an inventory write-down, the persistent accumulated deficit, and the one-time loss from debt extinguishment highlight ongoing financial pressures. The successful capital raise from Novel provides crucial liquidity and a strategic partnership, but future dilution from potential Growth Notes and macroeconomic headwinds impacting capital equipment purchases introduce uncertainty. The stock is not a 'strong buy' given the mixed financial performance and external risks, but the operational improvements and new capital prevent a 'sell' recommendation at this time.

Keywords

IRIDEX, IRIX, ophthalmology, medical technology, glaucoma, retinal diseases, MicroPulse, Cyclo G6, PASCAL, SEC filing, 10-Q, financial results, revenue growth, net loss, capital raise, Topcon, Novel Inspirational International, cost savings, inventory write-down

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.